BioSpace News Archive

Olema Pharmaceuticals, Inc. announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference in Boston on Wednesday, August 9, 2023, at 2:00 p.m. ET.

Replimune Group, Inc. today announced that members from the Replimune management team will present and host investor meetings at the following two conferences.

Ovid Therapeutics Inc. today announced that management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 7, 2023, at 9:30 a.m. ET.

Comera Life Sciences Holdings, Inc. announced that it has executed a definitive agreement to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders at a purchase price of $0.51125 per share.

Pasithea Therapeutics Corp. announced a publication in the internationally renowned scientific peer-reviewed journal Proceedings of the National Academy of Sciences, related to its PAS-003 drug discovery program, that describes an increased expression of α5/β1 integrin on motor neurons in ALS human and mouse tissue, as well as the blockade of this integrin as a potential new approach to treat ALS patients.

Immutep Limited today announces it has received positive scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the continued development of eftilagimod alpha (efti).

AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced positive topline data from its Phase 1 trial evaluating the company’s subcutaneously administered immune checkpoint enhancer (ICE), ALTB-268 in healthy volunteers.

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, announced the launch of its Early Lung Cancer Center.

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that InMode will participate at the following investor conferences and events in August.

iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases.